RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus
Beard, S., Gaffney, L., & Backhouse, M. (2001). An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. Journal of Medical Economics, 4, 199-205.
Cardiovascular disease (CVD) is a major cause of death and morbidity in the United Kingdom (UK) and carries with it a significant financial cost through health care resource use. More than one in three people die from CVD events, and the cost to the UK National Health Service (NHS) was £1.6 billion in 19961. The recently published MICRO-HOPE study evaluated the treatment of 3,577 patients at high risk for cardiovascular events from diabetes mellitus and demonstrated significant survival and morbidity benefits associated with ramipril.